NEOVAC-EC - Improving vaccination in early life (LIFE QUALITY) (2000-03-01 - 2003-02-28) (»add to infobox)

Michel GRECO, Gabriele BRUSA, William WAKEHAM, Jean CASTEX, Andre CAPRON, Tom CALLAGHAN, Jean-Luc BELINGARD, Ingrid KARLSSON, Jean-Louis VAN HERWEGHEM, Ilse VICKERS, André VIFIAN, James FOX

AVENTIS PASTEUR SA (FR716 - Rhône) (France), CHIRON SRL (IT519 - Siena) (Italy), IMPERIAL COLLEGE LONDON (UK550 - Greater London) (Great Britain), INSTITUT PASTEUR (FR101 - Paris) (France), INSTITUT PASTEUR DE LILLE (FR301 - Nord) (France), NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE002 - Dublin) (Ireland), PIERRE FABRE MEDICAMENT SA (FR718 - Haute-Savoie) (France), SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES (SE021 - Uppsala län) (Sweden), UNIVERSITE LIBRE DE BRUXELLES (BE100 - Arr. de Bruxelles-Capitale) (Belgium), UNIVERSITY COLLEGE LONDON (UK550 - Greater London) (Great Britain), UNIVERSITY OF GENEVA (CH013 - Genève) (Switzerland), UNIVERSITY OF LIVERPOOL (UK840 - Merseyside) (Great Britain)

The objectives of Neavac-Ec are :1) to increase knowledge of immunological factors which, in early infancy, lead to a high susceptibility to infectious diseases and to relatively weak vaccine-induced responses; 2) to define optimal vaccine design and new immunization strategies for the rapid induction, in early life, of protective vaccine responses and long lasting immunological memory; 3)to identify and standardize suitable evaluation procedures (in vitro/in vivo, animal models/human, Dendrite Cell (DC), T and B cells responses) for the initial assessment of future vaccines/ delivery systems/ adjuvant considered for use in early life. A Tran disease approach has been adopted, focusing on (I) analysis of the Maturation of early life immune responses in humans and animal models and (ii) optimisation of vaccines against 3 selected important early life pathogens (S.pneumoniae, B. peruses, Respiratory Syncytial Virus). This should contribute to establishing the generic principles of early life immunization and promote their concrete application to the industrial development of vaccines of high priority for both human and veterinary diseases.

PERSONS (12/12)

RELATED NAVIGATION AREA(S) (2/2)